About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 195691, 12 pages
http://dx.doi.org/10.1155/2013/195691
Clinical Study

Autologous CIK Cell Immunotherapy in Patients with Renal Cell Carcinoma after Radical Nephrectomy

1Biotherapeutic Department, Chinese PLA General Hospital, Beijing 100853, China
2Department of Cadre Health Care, Naval General Hospital, Beijing 100048, China

Received 30 September 2013; Accepted 13 November 2013

Academic Editor: Eyad Elkord

Copyright © 2013 Yajing Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Zhou, D. Weng, F. Zhou et al., “Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: In Vitro results and clinical responses,” Cancer Immunology, Immunotherapy, vol. 58, no. 10, pp. 1587–1597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. R. J. Motzer, N. H. Bander, and D. M. Nanus, “Medical progress: renal-cell carcinoma,” The New England Journal of Medicine, vol. 335, no. 12, pp. 865–875, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. J. A. Garcia and B. I. Rini, “Recent progress in the management of advanced renal cell carcinoma,” CA Cancer Journal for Clinicians, vol. 57, no. 2, pp. 112–125, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Yagoda, D. Petrylak, and S. Thompson, “Cytotoxic chemotherapy for advanced renal cell carcinoma,” Urologic Clinics of North America, vol. 20, no. 2, pp. 303–321, 1993. View at Scopus
  5. A. Shablak, R. E. Hawkins, D. G. Rothwell, and E. Elkord, “T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective,” Clinical Cancer Research, vol. 15, no. 21, pp. 6503–6510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. B. I. Rini, “New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance,” Clinical Cancer Research, vol. 16, no. 5, pp. 1348–1354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Dougan and G. Dranoff, “Immune therapy for cancer,” Annual Review of Immunology, vol. 27, pp. 83–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Hontscha, Y. Borck, H. Zhou, D. Messmer, and I. G. H. Schmidt-Wolf, “Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC),” Journal of Cancer Research and Clinical Oncology, vol. 137, no. 2, pp. 305–310, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Schwaab, A. Schwarzer, B. Wolf et al., “Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with aldesleukin (interleukin 2) and IFN-α2a therapy in metastatic renal cell carcinoma patients,” Clinical Cancer Research, vol. 15, no. 15, pp. 4986–4992, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. I. G. H. Schmidt-Wolf, P. Lefterova, B. A. Mehta et al., “Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells,” Experimental Hematology, vol. 21, no. 13, pp. 1673–1679, 1993. View at Scopus
  11. M. Sun, S. F. Shariat, C. Cheng et al., “Prognostic factors and predictive models in renal cell carcinoma: a contemporary review,” European Urology, vol. 60, no. 4, pp. 644–661, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. “Kidney,” in AJCC Cancer Staging Handbook, I. D. Fleming, J. S. Cooper, D. E. Henson, et al., Eds., pp. 356–358, Lippincott-Raven, Philadelphia, Pa, USA, 1998.
  13. P. Selby, “Measuring the quality of life in patients with cancer,” in Quality of Life Assessment: Key Issues in the 1990s, Kulwer Academic, London, UK, 1993.
  14. K. Yoshimura, T. Minami, M. Nozawa, et al., “Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma,” British Journal of Cancer, vol. 108, no. 6, pp. 1260–1266, 2013.
  15. N. J. Vogelzang, E. R. Priest, and L. Borden, “Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup,” Journal of Urology, vol. 148, no. 4, pp. 1247–1248, 1992. View at Scopus
  16. S. A. Rosenberg, J. C. Yang, S. L. Topalian et al., “Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2,” Journal of the American Medical Association, vol. 271, no. 12, pp. 907–913, 1994. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Negrier, B. Escudier, C. Lasset et al., “Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma,” The New England Journal of Medicine, vol. 338, no. 18, pp. 1272–1278, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Sangiolo, “Cytokine induced killer cells as promising immunotherapy for solid tumors,” Journal of Cancer, vol. 2, pp. 363–368, 2011.
  19. S. Rosenberg, “Lymphokine-activated killer cells: a new approach to immunotherapy of cancer,” Journal of the National Cancer Institute, vol. 75, no. 4, pp. 595–603, 1985. View at Scopus
  20. S. A. Rosenberg, P. Spiess, and R. Lafreniere, “A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes,” Science, vol. 233, no. 4770, pp. 1318–1321, 1986. View at Scopus
  21. Y.-S. Yun, M. E. Hargrove, and C.-C. Ting, “In Vivo antitumor activity of anti-CD3-induced activated killer cells,” Cancer Research, vol. 49, no. 17, pp. 4770–4774, 1989. View at Scopus
  22. A. Shablak, R. E. Hawkins, D. G. Rothwell, and E. Elkord, “T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective,” Clinical Cancer Research, vol. 15, no. 21, pp. 6503–6510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. E. A. Grimm, A. Mazumder, H. Z. Zhang, and S. A. Rosenberg, “Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes,” Journal of Experimental Medicine, vol. 155, no. 6, pp. 1823–1841, 1982. View at Scopus
  24. T. L. Whiteside, S. Miescher, and J. Hurlimann, “Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors,” International Journal of Cancer, vol. 37, no. 6, pp. 803–811, 1986. View at Scopus
  25. L. Mesler Muul, P. J. Spies, E. P. Director, and S. A. Rosenberg, “Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma,” Journal of Immunology, vol. 138, no. 3, pp. 989–995, 1987. View at Scopus
  26. L. Liu, W. Zhang, X. Qi et al., “Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma,” Clinical Cancer Research, vol. 18, no. 6, pp. 1751–1759, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. P. S. Goedegebuure, L. M. Douville, H. Li et al., “Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study,” Journal of Clinical Oncology, vol. 13, no. 8, pp. 1939–1949, 1995. View at Scopus
  28. R. L. Kradin, J. T. Kurnick, D. S. Lazarus et al., “Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer,” The Lancet, vol. 1, no. 8638, pp. 577–580, 1989. View at Scopus
  29. R. Ridolfi, E. Flamini, A. Riccobon et al., “Adjuvant adoptive immunotherapy tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients,” Cancer Immunology Immunotherapy, vol. 46, no. 4, pp. 185–193, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Atzpodien, H. Kirchner, U. Jonas et al., “Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN),” Journal of Clinical Oncology, vol. 22, no. 7, pp. 1188–1194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. C. Yang, L. Haworth, R. M. Sherry et al., “A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer,” The New England Journal of Medicine, vol. 349, no. 5, pp. 427–434, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Négrier, D. Perol, A. Ravaud et al., “Randomized study of intravenous versus subcutaneous interleukin-2, and IFNα in patients with good prognosis metastatic renal cancer,” Clinical Cancer Research, vol. 14, no. 18, pp. 5907–5912, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Olioso, R. Giancola, M. Di Riti, A. Contento, P. Accorsi, and A. Iacone, “Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial,” Hematological Oncology, vol. 27, no. 3, pp. 130–139, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. D. Sangiolo, E. Martinuzzi, M. Todorovic et al., “Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers,” International Immunology, vol. 20, no. 7, pp. 841–848, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Wang, J. Epler, L. G. Salazar, and S. R. Riddell, “Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1,” Cancer Research, vol. 66, no. 13, pp. 6826–6833, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Sangiolo, “Cytokine induced killer cells as promising immunotherapy for solid tumors,” Journal of Cancer, vol. 2, pp. 363–368, 2011.
  37. P.-H. Lu and R. S. Negrin, “A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency,” Journal of Immunology, vol. 153, no. 4, pp. 1687–1696, 1994. View at Scopus
  38. S. H. Thorne, R. S. Negrin, and C. H. Contag, “Synergistic antitumor effects of immune cell-viral biotherapy,” Science, vol. 311, no. 5768, pp. 1780–1784, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. T. Calzascia, M. Pellegrini, H. Hall et al., “TNF-α is critical for antitumor but not antiviral T cell immunity in mice,” Journal of Clinical Investigation, vol. 117, no. 12, pp. 3833–3845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Edinger, Y.-A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin, “Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging,” Blood, vol. 101, no. 2, pp. 640–648, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. M. R. Verneris, M. Kornacker, V. Mailander, and R. S. Negrin, “Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis,” Cancer Immunology Immunotherapy, vol. 49, no. 6, pp. 335–345, 2000. View at Scopus
  42. I. G. H. Schmidt-Wolf, R. S. Negrin, H.-P. Kiem, K. G. Blume, and I. L. Weissman, “Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity,” Journal of Experimental Medicine, vol. 174, no. 1, pp. 139–149, 1991. View at Scopus
  43. I. G. H. Schmidt-Wolf, S. Finke, B. Trojaneck et al., “Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-1 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma,” British Journal of Cancer, vol. 81, no. 6, pp. 1009–1016, 1999. View at Publisher · View at Google Scholar · View at Scopus